Striatal plasticity and extrapyramidal motor dysfunction

Parkinsonism and Related Disorders

Volumn 10, Issue 5, 2004, Pages 305-313

  Chase, Thomas N ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Adenosine; alpha amino 3 hydroxy 5 methyl 4 isoxazole proprionic acid; Dopamine; Dyskinesia; Fluctuations; Glutamate; Levodopa; N methyl D aspartate; Parkinson's disease; Phosphorylation; Serotonin

Indexed keywords

2,6 DIAMINO N [[1 (1 OXOTRIDECYL) 2 PIPERIDYL]METHYL]HEXANAMIDE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMANTADINE; AMPA RECEPTOR; CO 101244; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DEXTROMETHORPHAN; DEXTRORPHAN; DOPAMINE RECEPTOR; GENISTEIN; GLUTAMATE RECEPTOR; IFENPRODIL; IONOTROPIC RECEPTOR; ISTRADEFYLLINE; LEVODOPA; MD 100453; MDL 100453; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OKADAIC ACID; PD 174494; PHOSPHOTRANSFERASE INHIBITOR; QUETIAPINE; SERINE; TALAMPANEL; TRAXOPRODIL; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BRAIN CORTEX; BRAIN NERVE CELL; CLINICAL FEATURE; CONFERENCE PAPER; CORPUS STRIATUM; DENERVATION; DISEASE ASSOCIATION; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG EFFECT; EFFERENT NERVE; EXTRAPYRAMIDAL SYNDROME; HUMAN; MOLECULAR BIOLOGY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NONHUMAN; PARKINSON DISEASE; PATIENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; SCIENCE; SIGNAL TRANSDUCTION; STANDARD; STIMULATION; SYNAPSE;

ANIMALS; BASAL GANGLIA DISEASES; CORPUS STRIATUM; HUMANS; MOTOR SKILLS DISORDERS; NEURONAL PLASTICITY;

EID: 2942541214     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2004.02.012     Document Type: Conference Paper

References (106)

1. Silva A.J. Molecular and cellular cognitive studies of the role of synaptic plasticity in memory. J Neurobiol. 54:2003;224-237
2. Arbuthnott G.W., Ingham C.A., Wickens J.R. Dopamine and synaptic plasticity in the neostriatum. J Anat. 196:2000;587-596
3. Centonze D., Picconi B., Gubellini P., Bernardi G., Calabresi P. Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur J Neurosci. 13:2001;1071-1077
4. Jay T.M. Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol. 69:2003;375-390
5. Chase T.N., Oh J.D. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol. 47:2000;S122-S130
6. Lin J.Y., Dubey R., Funk G.D., Lipski J. Receptor subtype-specific modulation by dopamine of glutamatergic responses in striatal medium spiny neurons. Brain Res. 959:2003;251-262
7. Schultz W. Behavior-related activity of primate dopamine neurons. Rev Neurol (Paris). 150:1994;634-639
8. Yung K.K., Bolam J.P., Smith A.D., Hersch S.M., Ciliax B.J., Levey A.I. Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience. 65:1995;709-730
9. Caillé I., Dumartin B., Bloch B. Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res. 730:1996;17-31
10. Zoli M., Torri C., Ferrari R., Jansson A., Zini I., Fuxe K., Agnati L.F. The emergence of the volume transmission concept. Brain Res Brain Res Rev. 26:1998;136-147
11. Skirboll S., Wang J., Mefford I., Hsiao J., Bankiewicz K.S. In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. Exp Neurol. 110:1990;187-193
12. Sarre S., De Klippel N., Herregodts P., Ebinger G., Michotte Y. Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis. Naunyn Schmiedebergs Arch Pharmacol. 350:1994;15-21
13. Juncos J.L., Engber T.M., Raisman R., Susel Z., Thibaut F., Ploska A., Agid Y., Chase T.N. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol. 25:1989;473-478
14. Mouradian M.M., Heuser I.J., Baronti F., Fabbrini G., Juncos J.L., Chase T.N. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol. 25:1989;523-526
15. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington, Clinical, morphological and neurochemical correlations. J Neurol Sci. 20:1973;415-455
16. Fabbrini G., Mouradian M.M., Juncos J.L., Schlegel J., Mohr E., Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms Part I. Ann Neurol. 24:1988;366-371
17. Mouradian M.M., Juncos J.L., Fabbrini G., Schlegel J., Mohr E., Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms Part II. Ann Neurol. 24:1988;372-378
18. Chase T.N., Watanabe A.M. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism. Neurology. 22:1972;384-392
19. Lloyd K.G., Davidson L., Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther. 195:1975;453-464
20. Chase T.N., Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23:2000;S86-S91
21. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 662:1994;69-74
22. Engber T.M., Susel Z., Kuo S., Gerfen C.R., Chase T.N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 552:1991;113-118
23. Taylor M.D., De Ceballos M.L., Rose S., Jenner P., Marsden C.D. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3, 4- dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Eur J Pharmacol. 219:1992;183-192
24. Tel B.C., Zeng B.Y., Cannizzaro C., Pearce R.K., Rose S., Jenner P. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience. 115:2002;1047-1058
25. Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis. 10:2002;165-186
26. Marin C., Engber T.M., Chaudhuri P., Peppe A., Chase T.N. Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors. Psychopharmacology (Berl). 123:1996;215-221
27. Boules M., Warrington L., Fauq A., McCormick D., Richelson E. Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats. Eur J Pharmacol. 428:2001;227-233
28. Chen M.T., Morales M., Woodward D.J., Hoffer B.J., Janak P.H. In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions. Exp Neurol. 171:2001;72-83
29. Barnes G.N., Slevin J.T. Ionotropic glutamate receptor biology: effect on synaptic connectivity and function in neurological disease. Curr Med Chem. 10:2003;2059-2072
30. Koles L., Wirkner K., Illes P. Modulation of ionotropic glutamate receptor channels. Neurochem Res. 26:2001;925-932
31. Carroll R.C., Zukin R.S. NMDA-receptor trafficking and targeting: implications for synaptic transmission and plasticity. Trends Neurosci. 25:2002;571-577
32. Stefani A., Chen Q., Flores-Hernandez J., Jiao Y., Reiner A., Surmeier D.J. Physiological and molecular properties of AMPA/Kainate receptors expressed by striatal medium spiny neurons. Dev Neurosci. 20:1998;242-252
33. Swope S.L., Moss S.I., Raymond L.A., Huganir R.L. Regulation of ligand-gated ion channels by protein phosphorylation. Adv Second Messenger Phosphoprotein Res. 33:1999;49-78
34. Kotecha S.A., MacDonald J.F. Signaling molecules and receptor transduction cascades that regulate NMDA receptor-mediated synaptic transmission. Int Rev Neurobiol. 54:2003;51-106
35. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol Rev. 51:1999;7-61
36. Dunah A.W., Yasuda R.P., Luo J., Wang Y., Prybylowski K.L., Wolfe B.B. Biochemical studies of the structure and function of the N-methyl-D-aspartate subtype of glutamate receptors. Mol Neurobiol. 19:1999;151-179
37. Sesack S.R., Aoki C., Pickel V.M. Ultrastructural localalization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci. 14:1994;88-106
38. Suen P.C., Wu K., Xu J.L., Lin S.Y., Levine E.S., Black I.B. NMDA receptor subunits in the postsynaptic density of rat brain: expression and phosphorylation by endogenous protein kinases. Brain Res Mol Brain Res. 59:1998;215-228
39. Nishi A., Bibb J.A., Matsuyama S., Hamada M., Higashi H., Nairn A.C., Greengard P. Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. J Neurochem. 81:2002;832-841
40. Ali D.W., Salter M.W. NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity. Curr Opin Neurobiol. 11:2001;336-342
41. Menegoz M., Lau L.F., Herve D., Huganir R.L., Girault J.A. Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. Neuro Report. 7:1995;125-128
42. Oh J.D., Russell D.S., Vaughan C.L., Chase T.N., Russell D. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res. 813:1998;150-159
43. Dunah A.W., Wang Y., Yasuda R.P., Kameyama K., Huganir R.L., Wolfe B.B., Standaert D.G. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol. 57:2000;342-352
44. Lai S.K., Tse Y.C., Yang M.S., Wong C.K., Chan Y.S., Yung K.K. Gene expression of glutamate receptors GluR1 and NR1 is differentially modulated in striatal neurons in rats after 6-hydroxydopamine lesion. Neurochem Int. 43:2003;639-653
45. Song I., Huganir R.L. Regulation of AMPA receptors during synaptic plasticity. Trends Neurosci. 25:2002;578-588
46. Fan X.D., Li X.M., Ashe P.C., Juorio A.V. Lesion of the substantia nigra pars compacta downregulates striatal glutamate receptor subunit mRNA expression. Brain Res. 850:1999;79-86
47. Tingley W.G., Ehlers M.D., Kameyama K., Doherty C., Ptak J.B., Riley C.T., Huganir R.L. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-d-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J Biol Chem. 272:1997;5157-5166
48. Liao G.Y., Wagner D.A., Hsu M.H., Leonard J.P. Evidence for direct protein kinase-C mediated modulation of N-methyl-D-aspartate receptor current. Mol Pharmacol. 59:2001;960-964
49. Mayadevi M., Praseeda M., Kumar K.S., Omkumar R.V. Sequence determinants on the NR2A and NR2B subunits of NMDA receptor responsible for specificity of phosphorylation by CaMKII. Biochim Biophys Acta. 1598:2002;40-45
50. Oh J.D., Vaughan C.L., Chase T.N. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res. 82:1999;433-442
51. Carvalho A.L., Duarte C.P., Carvalho A.P. Regulation of AMPA receptors by phosphorylation. Neurochem Res. 25:2000;1245-1255
52. Esteban J.A., Shi S.H., Wilson C., Nuriya M., Huganir R.L., Malinow R. PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nat Neurosci. 6:2003;136-143
53. Chao S.Z., Lu W., Lee H.K., Huganir R.L., Wolf M.E. D(1) dopamine receptor stimulation increases GluR1 phosphorylation in postnatal nucleus accumbens cultures. J Neurochem. 81:2002;984-992
54. Oh J.D., Geller A.I., Zhang G., Chase T.N. Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 971:2003;18-30
55. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli N., Chen J.F., Schwarzschild M.A., Chase T.N. A(2A) antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol. 184:2003;285-294
56. Lee F.J., Xue S., Pei L., Vukusic B., Chery N., Wang Y., Wang Y.T., Niznik H.B., Yu X.M., Liu F. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell. 111:2002;219-230
57. Oh J.D., Del Dotto P., Chase T.N. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci Lett. 228:1997;5-8
58. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport. 5:1994;2586-2588
59. Papa S.M., Boldry R.C., Engber T.M., Kask A.M., Chase T.N. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701:1995;13-18
60. Marin C., Papa S.M., Engber T.M., Bonastre M., Tolosa E., Chase T.N. MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736:1996;202-205
61. Loschmann P.A., Wullner U., Heneka M.T., Schulz J.B., Kunow M., Wachtel H., Klockgether T. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Synapse. 26:1997;381-391
62. Boldry R.C., Chase T.N., Engber T.M. Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions. J Pharmacol Exp Ther. 267:1993;1454-1459
63. Fredriksson A., Palomo T., Chase T., Archer T. Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists. J Neural Transm. 106:1999;283-300
64. Marin C., Jimenez A., Bonastre M., Chase T.N., Tolosa E. Non-NMDA receptor mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats. Synapse. 36:2000;267-274
65. Blanchet P.J., Konitsiotis S., Chase T.N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord. 13:1998;798-802
66. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol. 39:1996;574-578
67. Blanchet P.J., Papa S.M., Metman L.V., Mouradian M.M., Chase T.N. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci Biobehav Rev. 21:1997;447-453
68. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev. 21:1997;455-468
69. Blanchet P.J., Metman L.V., Mouradian M.M., Chase T.N. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord. 11:1996;580-581
70. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50:1998;1323-1326
71. Verhagen Metman L., Del Dotto P., Natte R., van den Munckhof P., Chase T.N. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology. 51:1998;203-206
72. Metman L.V., Del Dotto P., LePoole K., Konitsiotis S., Fang J., Chase T.N. Amantadine for levodopa- induced dyskinesias: a 1-year follow-up study. Arch Neurol. 56:1999;1383-1386
73. Luginger E., Wenning G.K., Bosch S., Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord. 15:2000;873-878
74. Nash J.E., Fox S.H., Henry B., Hill M.P., Peggs D., McGuire S., Maneuf Y., Hille C., Brotchie J.M., Crossman A.R. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol. 165:2000;136-142
75. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Menniti F.S., Greenamyre J.T. Antiparkinsonian actions of CP-101, 606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol. 163:2000;239-243
76. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N- methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4- phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther. 290:1999;1034-1040
77. Jimenez A., Bonastre M., Vila M., Agid Y., Hirsch E.C., Tolosa E. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse. 42:2001;40-47
78. Marin C., Jimenez A., Bonastre M., Vila M., Agid Y., Hirsch E.C., Tolosa E. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse. 42:2001;40-47
79. Klockgether T., Turski L., Honore T., Zhang Z.M., Gash D.M., Kurlan R., Greenamyre J.T., The A.M.P.A. receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol. 30:1991;717-723
80. Luquin M.R., Obeso J.A., Laguna J., Guillen J., Martinez-Lage J.M., The A.M.P.A. receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur J Pharmacol. 235:1993;297-300
81. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 54:2000;1589-1595
82. Merims D., Ziv I., Djaldetti R., Melamed E. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet. 353:1999;1764-1765
83. Ballard P.A., Tetrud J.W., Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): seven cases. Neurology. 35:1985;949-956
84. Onofrj M., Paci C., Thomas A. Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease. J Neurol Neurosurg Psychiatry. 65:1998;605-606
85. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol. 247:(Suppl 2):2000;1143-1150
86. Di Monte D.A., McCormack A., Petzinger G., Janson A.M., Quik M., Langston W.J. Nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord. 15:2000;459-466
87. Mouradian M.M., Heuser I.J., Baronti F., Chase T.N. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol. 27:1990;18-23
88. Baronti F., Mouradian M.M., Davis T.L., Giuffra M., Brughitta G., Conant K.E., Chase T.N. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol. 32:1992;776-781
89. Hadj Tahar A., Gregoire L., Bangassoro E., Bedard P.J. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol. 23:2000;195-202
90. Andersson M., Konradi C., Cenci M.A. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci. 21:2001;9930-9943
91. Balschun D., Wolfer D.P., Gass P., Mantamadiotis T., Welzl H., Schutz G., Frey J.U., Lipp H.P. Does cAMP response element-binding protein have a pivotal role in hippocampal synaptic plasticity and hippocampus-dependent memory? J Neurosci. 23:2003;6304-6314
92. Colombo P.J., Brightwell J.J., Countryman R.A. Cognitive strategy-specific increases in phosphorylated cAMP response element-binding protein and c-Fos in the hippocampus and dorsal striatum. J Neurosci. 23:2003;3547-3554
93. Oh J.D., Chartisathian K., Ahmed S.M., Chase T.N., Cyclic A.M.P. responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats. J Neurosci Res. 72:2003;768-780
94. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci. 6:2003;501-506
95. Hillion J., Canals M., Torvinen M., Casado V., Scott R., Terasmaa A., Hansson A., Watson S., Olah M.E., Mallol J., Canela E.I., Zoli M., Agnati L.F., Ibanez C.F., Lluis C., Franco R., Ferre S., Fuxe K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem. 277:2002;18091-18097
96. Fredholm B.B., Arslan G., Halldner L., Kull B., Schulte G., Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol. 362:2000;364-374
97. Shindou T., Nonaka H., Richardson P.J., Mori A., Kase H., Ichimura M. Presynaptic adenosine A2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus. Br J Pharmacol. 136:2002;296-302
98. Kanda T., Jackson M.J., Smith L.A., Pearce R.K., Nakamura J., Kase H., Kuwana Y., Jenner P. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 43:1998;507-513
99. Grondin R., Bedard P.J., Hadj Tahar A., Gregoir L., Mori A., Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology. 52:1999;1673-1677
100. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., Chase T.N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology. 61:2003;293-296
101. Hauser R.A., Hubble J.P., Truong D.D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 61:2003;297-303
102. Rodriguez J.J., Garcia D.R., Pickel V.M. Subcellular distribution of 5-hydroxytryptamine 2A and N-methyl-D-aspartate receptors within single neurons in rat motor and limbic striatum. J Comp Neurol. 413:1999;219-231
103. Inoue T., Itoh S., Kobayashi M., Kang Y., Matsuo R., Wakisaka S., Morimoto T. Serotonergic modulation of the hyperpolarizing spike afterpotential in rat jaw-closing motoneurons by PKA and PKC. J Neurophysiol. 82:1999;626-637
104. Hasuo H., Matsuoka T., Akasu T. Activation of presynaptic 5-hydroxytryptamine 2A receptors facilitates excitatory synaptic transmission via protein kinase C in the dorsolateral septal nucleus. J Neurosci. 22:2002;7509-7517
105. Oh J.D., Bibbiani F., Chase T.N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol. 177:2002;557-564
106. Rahimian R., Hrdina P.D. Possible role of protein kinase C in regulation of 5-hydroxytryptamine 2A receptors in rat brain. Can J Physiol Pharmacol. 73:1995;1686-1691